<--- Back to Details
First PageDocument Content
Monoclonal antibodies / Immunosuppressants / Immunology / Biotechnology / Immune system / Adalimumab / Tocilizumab / Infliximab / Monoclonal antibody therapy / Disease-modifying antirheumatic drug / TNF inhibitor / Rheumatology
Date: 2015-06-19 09:17:30
Monoclonal antibodies
Immunosuppressants
Immunology
Biotechnology
Immune system
Adalimumab
Tocilizumab
Infliximab
Monoclonal antibody therapy
Disease-modifying antirheumatic drug
TNF inhibitor
Rheumatology

TABLE OF CONTENTS INTRODUCTION 2

Add to Reading List

Source URL: www.abirisk.eu

Download Document from Source Website

File Size: 758,62 KB

Share Document on Facebook

Similar Documents

EAP Reimbursement Criteria for Frequently Requested Drugs

EAP Reimbursement Criteria for Frequently Requested Drugs

DocID: 1rhhE - View Document

TABLE OF CONTENTS  INTRODUCTION 2

TABLE OF CONTENTS INTRODUCTION 2

DocID: 1qY7G - View Document

JUNE 2015 TABLE OF CONTENTS  INTRODUCTION

JUNE 2015 TABLE OF CONTENTS INTRODUCTION

DocID: 1qDC6 - View Document

Provincial Drug Programs P. O. Box 2000 Charlottetown PE C1A 7N8Toll Free on PEI)  Programmes provinciaux de médicaments

Provincial Drug Programs P. O. Box 2000 Charlottetown PE C1A 7N8Toll Free on PEI) Programmes provinciaux de médicaments

DocID: 1qAvE - View Document

TABLE OF CONTENTS  INTRODUCTION 2

TABLE OF CONTENTS INTRODUCTION 2

DocID: 1qs3R - View Document